Costco Enters Weight-Loss Market with Ozempic and Wegovy

Costco's New Offerings in Weight Management

In a significant move, Costco will soon make the sought-after weight-loss medications, Ozempic and Wegovy, available at its more than 500 pharmacies across the United States. Priced at $499 for a month's supply, the cost mirrors that of CVS and Walmart but presents an opportunity for Costco members to gain both affordability and convenience.

"We continue to find new ways to make access to our medicines more convenient, meeting people where they are," stated a spokesperson from Novo Nordisk.

The Battle for Market Share

The decision by Novo Nordisk, the Danish manufacturer of these drugs, reflects its urgency to hold market share against a flood of cheaper alternatives. As prescription-only medications, Ozempic and Wegovy are expected to enhance Costco's pharmacy services while offering members rare access to these innovative therapeutic options.

Currently, many patients are paying out of pocket, as health insurance plans remain inconsistent in their coverage for these medications. For those without insurance, the Costco pricing offers a potentially more manageable way to access these drugs, which employ semaglutide, a synthetic hormone that mimics the effects of glucagon-like peptide-1 (GLP-1).

Market Context and Implications

This offering comes at a time when Novo Nordisk is feeling the pinch of increased competition and declining share prices, down over 50% this year. Despite reporting robust revenues—in excess of $24 billion in the first half of 2025—its outlook remains cautious. Adding a powerhouse like Costco to its distribution network could attract a vast number of new customers, particularly as over 100 million individuals shop at Costco stores.

Pricing and Insurance Factors

• Costco's standard price for both Ozempic and Wegovy stands at $499 per month, representing substantial savings compared to their list prices.
• Moreover, Costco's executive members and Citibank credit card holders can enjoy additional cash-back incentives, further enhancing value.
• For those with private health insurance, the ultimate cost of the drugs will hinge on their specific plans.

Consumer Response and Future Outlook

As consumer interest in weight-loss solutions rises, it's anticipated that a greater number of patients will turn to GLP-1 medications. In fact, Morgan Stanley predicts that drug users could swell from 7 million today to 24 million by 2035. This growing demand indicates a significant shift in consumer attitudes toward weight management—an issue underscore by a study showing a more than 700% increase in prescriptions for non-diabetic, overweight patients from 2019 to 2023.

Final Thoughts

The introduction of Ozempic and Wegovy at Costco could signify a pivotal change in how Americans approach weight management. With growing health concerns related to obesity, the availability of effective, albeit pricey, medications may prompt further discussions around healthcare access and affordability. As we navigate this evolving landscape, the implications for both consumer health and pharmaceutical accessibility will be profound.